Gualtiero Palareti

Gualtiero Palareti's AcademicInfluence.com Rankings

Gualtiero Palareti

Philosophy

#11109

Historical Rank

Logic

#6215

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Gualtiero Palareti's Degrees

PhD Medical Sciences University of Bologna
Doctorate Medicine University of Bologna

Why Is Gualtiero Palareti Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Gualtiero Palareti's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). (2008) (2191)
Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT) (1996) (1432)
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. (2012) (1301)
D-dimer testing to determine the duration of anticoagulation therapy. (2006) (527)
Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies: a four-year prospective study from the Italian Registry. (1996) (444)
Comparison between different D‐Dimer cutoff values to assess the individual risk of recurrent venous thromboembolism: analysis of results obtained in the DULCIS study (2016) (435)
Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis (2012) (395)
Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH) (2012) (379)
Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. (2010) (319)
Risk of Venous Thromboembolism Recurrence: High Negative Predictive Value of D-dimer Performed after Oral Anticoagulation Is Stopped (2002) (315)
Aprotinin and transfusion requirements in orthotopic liver transplantation: a multicentre randomised double-blind study (2000) (297)
Predictive Value of D‐Dimer Test for Recurrent Venous Thromboembolism After Anticoagulation Withdrawal in Subjects With a Previous Idiopathic Event and in Carriers of Congenital Thrombophilia (2003) (269)
Bleeding risk assessment and management in atrial fibrillation patients (2011) (247)
A Comparison of the Safety and Efficacy of Oral Antiocoagulation for the Treatment of Venous Thromboembolic Disease in Patients with or without Malignancy (2000) (244)
Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. (2018) (236)
Bleeding with anticoagulation therapy – Who is at risk, and how best to identify such patients (2009) (231)
Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. (2011) (216)
Does the clinical presentation and extent of venous thrombosis predict likelihood and type of recurrence? A patient‐level meta‐analysis (2010) (200)
Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT) (2005) (197)
Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment: Results of a Prospective Collaborative Study on Elderly Patients Followed by Italian Centres for Anticoagulation (2011) (193)
First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. (2004) (183)
The heterozygous 20210 G/A prothrombin genotype is associated with early venous thrombosis in inherited thrombophilias and is not increased in frequency in artery disease. (1997) (180)
High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism (2008) (178)
Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). (2011) (170)
Patient-Level Meta-analysis: Effect of Measurement Timing, Threshold, and Patient Age on Ability of d-Dimer Testing to Assess Recurrence Risk After Unprovoked Venous Thromboembolism (2010) (170)
D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study. (2014) (169)
Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. (2000) (162)
Evidence-Based Clinical Practice Guidelines ed: American College of Chest Physicians Therapy and Prevention of Thrombosis, 9th Oral Anticoagulant Therapy : Antithrombotic (2012) (161)
Oral Anticoagulant Therapy in Patients with Nonrheumatic Atrial Fibrillation and Risk of Bleeding (2001) (160)
Deep-vein thrombosis in patients with multiple myeloma receiving first-line thalidomide-dexamethasone therapy. (2002) (156)
Risk of venous thromboembolism and clinical manifestations in carriers of antithrombin, protein C, protein S deficiency, or activated protein C resistance: a multicenter collaborative family study. (1999) (150)
Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study. (2010) (147)
Long‐term outcomes of patients with cerebral vein thrombosis: a multicenter study (2012) (139)
Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience (2020) (139)
Thrombotic Events during Oral Anticoagulant Treatment: Results of the Inception-cohort, Prospective, Collaborative ISCOAT Study (1997) (138)
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis (2019) (136)
Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: Results observed in four anticoagulation clinics. (2016) (131)
Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER Registry (2008) (130)
An international multicenter randomized study of computer‐assisted oral anticoagulant dosage vs. medical staff dosage (2008) (126)
D-dimer testing to determine the duration of anticoagulation therapy (2007) (125)
Warfarin Withdrawal (1996) (122)
Isolated distal deep vein thrombosis: what we know and what we are doing (2012) (120)
Activation of Blood Coagulation after Abrupt or Stepwise Withdrawal of Oral Anticoagulants - A Prospective Study (1994) (115)
Risks factors for highly unstable response to oral anticoagulation: a case‐control study (2005) (112)
Poor anticoagulation quality in the first 3 months after unprovoked venous thromboembolism is a risk factor for long‐term recurrence (2005) (111)
Low drug levels and thrombotic complications in high‐risk atrial fibrillation patients treated with direct oral anticoagulants (2018) (107)
D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis (2005) (105)
Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia (2005) (104)
Risk of recurrent venous thromboembolism after stopping treatment in cohort studies: recommendation for acceptable rates and standardized reporting (2010) (102)
Using an age-dependent D-dimer cut-off value increases the number of older patients in whom deep vein thrombosis can be safely excluded (2012) (101)
Evolution of untreated calf deep-vein thrombosis in high risk symptomatic outpatients: The blind, prospective CALTHRO study (2010) (99)
Markers of Procoagulant Imbalance in Patients with Inherited Thrombophilic Syndromes (1992) (98)
How I treat isolated distal deep vein thrombosis (IDDVT). (2014) (97)
Antithrombin III (ATIII) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. (1998) (95)
Sulodexide for the Prevention of Recurrent Venous Thromboembolism (2015) (94)
The first ambulatory screening on thromboembolism: a multicentre, cross‐sectional, observational study on risk factors for venous thromboembolism (2005) (94)
Coagulative Disorders in Human Acute Pancreatitis: Role for the D-Dimer (2003) (94)
Familial thrombophilia and lifetime risk of venous thrombosis (2004) (93)
The MASTER registry on venous thromboembolism: description of the study cohort. (2008) (90)
The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. (1995) (90)
Hereditary thrombophilia and fetal loss: a prospective follow‐up study (2004) (87)
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. (2002) (84)
Antithrombin III (ATILL) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study (1998) (76)
Impact of residual pulmonary obstruction on the long-term outcome of patients with pulmonary embolism (2017) (74)
Transcatheter patent foramen ovale closure mitigates aura migraine headaches abolishing spontaneous right-to-left shunting. (2006) (74)
Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data (2015) (72)
D‐dimer levels and 15‐day outcome in acute pulmonary embolism. Findings from the RIETE Registry (2009) (70)
Isolated distal deep vein thrombosis: efficacy and safety of a protocol of treatment. Treatment of Isolated Calf Thrombosis (TICT) Study. (2009) (64)
Thrombosis and thrombocytopenia in antiphospholipid syndrome (idiopathic and secondary to SLE): first report from the Italian Registry. Italian Registry of Antiphospholipid Antibodies (IR-APA). (1993) (64)
Poor comparability of coagulation screening test with specific measurement in patients receiving direct oral anticoagulants: results from a multicenter/multiplatform study (2016) (64)
Recurrence of ICH after resumption of anticoagulation with VK antagonists (2014) (64)
A multicentre randomised assessment of the DAWN AC computer-assisted oral anticoagulant dosage program (2009) (63)
Value of family history in identifying women at risk of venous thromboembolism during oral contraception: observational study (2001) (62)
A randomized double‐blind study of low‐molecular‐weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum) (2012) (61)
Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants (2019) (61)
Factors associated with the timing of diagnosis of venous thromboembolism: results from the MASTER registry. (2008) (59)
Safety and feasibility of a diagnostic algorithm combining clinical probability, d-dimer testing, and ultrasonography for suspected upper extremity deep venous thrombosis: a prospective management study. (2013) (59)
External validation of the DASH prediction rule: a retrospective cohort study (2017) (59)
Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia. (2004) (58)
The Wells rule and D‐dimer for the diagnosis of isolated distal deep vein thrombosis (2012) (57)
Hyperhomocyst(e)inemia and a common methylenetetrahydrofolate reductase mutation (Ala223Val MTHFR) in patients with inherited thrombophilic coagulation defects. (1997) (57)
Evaluation of a new automated panel of assays for the detection of anti-PF4/heparin antibodies in patients suspected of having heparin-induced thrombocytopenia (2010) (57)
Blood coagulation changes in homocystinuria: effects of pyridoxine and other specific therapy. (1986) (56)
Accuracy of a portable prothrombin time monitor (Coagucheck) in patients on chronic oral anticoagulant therapy: a prospective multicenter study. (2000) (55)
Practice Guidelines (8th Edition) Chest Physicians Evidence-Based Clinical Vitamin K Antagonists: American College of Pharmacology and Management of the (2008) (54)
Abnormally short activated partial thromboplastin time values are associated with increased risk of recurrence of venous thromboembolism after oral anticoagulation withdrawal (2006) (54)
Fibrinogen assays: a collaborative study of six different methods. C.I.S.M.E.L. Comitato Italiano per la Standardizzazione dei Metodi in Ematologia e Laboratorio. (1991) (54)
D-dimer for the diagnosis of upper extremity deep and superficial venous thrombosis. (2015) (53)
Plasma MMP–2 and MMP–9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation (2004) (53)
Analysis of agreement between Duplex ultrasound scanning and arteriography in patients with lower limb artery disease (2007) (53)
Residual emboli on lung perfusion scan or multidetector computed tomography after a first episode of acute pulmonary embolism (2011) (51)
Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. (2003) (51)
Aprotinin in orthotopic liver transplantation: Evidence for a prohemostatic, but not a prothrombotic, effect (2001) (50)
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation (2015) (49)
Prolonged very low calorie diet in highly obese subjects reduces plasma viscosity and red cell aggregation but not fibrinogen. (1994) (49)
Residual venous obstruction, alone and in combination with D-dimer, as a risk factor for recurrence after anticoagulation withdrawal following a first idiopathic deep vein thrombosis in the prolong study. (2010) (49)
The role of D-dimer and residual venous obstruction in recurrence of venous thromboembolism after anticoagulation withdrawal in cancer patients. (2005) (48)
Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). (2000) (45)
Italian intersociety consensus on DOAC use in internal medicine (2017) (44)
Gender differences of bleeding and stroke risk in very old atrial fibrillation patients on VKA treatment: results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). (2013) (44)
D-dimer and residual vein obstruction as risk factors for recurrence during and after anticoagulation withdrawal in patients with a first episode of provoked deep-vein thrombosis (2011) (43)
Two years outcome of isolated distal deep vein thrombosis. (2014) (43)
A new rapid bedside assay for d‐dimer measurement (Simplify d‐dimer) in the diagnostic work‐up for deep vein thrombosis (2003) (42)
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study (2013) (42)
Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. (2012) (42)
Multicenter evaluation of a new quantitative highly sensitive D-dimer assay, the Hemosil D-dimer HS 500, in patients with clinically suspected venous thromboembolism. (2010) (41)
A multicenter evaluation of a new quantitative highly sensitive D-dimer assay for exclusion of venous thromboembolism (2008) (41)
A multicentre randomised clinical endpoint study of parma 5 computer‐assisted oral anticoagulant dosage (2008) (41)
Management of patients with patent foramen ovale and cryptogenic stroke: A collaborative, multidisciplinary, position paper (2013) (40)
Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists (2012) (39)
Use of D-dimer testing to determine duration of anticoagulation, risk of cardiovascular events and occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study (2009) (38)
Prothrombin Molise: a "new" congenital dysprothrombinemia, double heterozygosis with an abnormal prothrombin and "true" prothrombin deficiency. (1978) (38)
Comparison of new rapid methods for D-dimer measurement to exclude deep vein thrombosis in symptomatic outpatients. (1997) (37)
Different cut-off values of quantitative D-dimer methods to predict the risk of venous thromboembolism recurrence: a post-hoc analysis of the PROLONG study (2008) (37)
Spontaneous large right-to-left shunt and migraine headache with aura are risk factors for recurrent stroke in patients with a patent foramen ovale. (2007) (37)
Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study. (2018) (36)
Pharmacodynamics of low molecular weight heparin in patients undergoing bariatric surgery: a prospective, randomised study comparing two doses of parnaparin (BAFLUX study). (2009) (36)
Diurnal changes of fibrinolysis in patients with liver cirrhosis and esophageal varices (2000) (36)
Risk of deep vein thrombosis: interaction between oral contraceptives and high factor VIII levels. (2004) (36)
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms (2012) (36)
Association of Reduced Factor VIII with Impaired Platelet Reactivity to Adrenalin and Collagen after Total Thyroidectomy (1989) (36)
Sex, age and normal post‐anticoagulation D‐dimer as risk factors for recurrence after idiopathic venous thromboembolism in the Prolong study extension (2010) (35)
Significance of plasma fibrinopeptide A and high molecular weight fibrinogen in patients with liver cirrhosis (1982) (35)
Predicting the risk of recurrence of venous thromboembolism (2004) (34)
Recurrent Venous Thromboembolism: What Is the Risk and How to Prevent It (2012) (34)
Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution. (2019) (34)
Contribution of a new, rapid, quantitative and automated method for D-dimer measurement to exclude deep vein thrombosis in symptomatic outpatients. (1999) (33)
D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. (2009) (33)
The risk of a first and a recurrent venous thrombosis associated with an elevated D‐dimer level and an elevated thrombin potential: results of the THE‐VTE study: comment (2015) (33)
The cost‐effectiveness of computer‐assisted anticoagulant dosage: results from the European Action on Anticoagulation (EAA) multicentre study (2009) (33)
The factor VIII D1241E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels (2005) (33)
Diagnosis and treatment of pulmonary embolism: a multidisciplinary approach (2013) (33)
Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20 years ago (2017) (33)
New anticoagulant drugs for treatment of venous thromboembolism and stroke prevention in atrial fibrillation (2012) (32)
Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry (2018) (32)
Influence of age, sex and vitamin status on fasting and post-methionine load plasma homocysteine levels. (2002) (32)
Long‐term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke (2006) (31)
Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery (2011) (31)
Management of cerebral and splanchnic vein thrombosis associated with thrombocytopenia in subjects previously vaccinated with Vaxzevria (AstraZeneca): a position statement from the Italian Society for the Study of Haemostasis and Thrombosis (SISET). (2021) (31)
Coagulation and Fibrinolysis in Orthotopic Liver Transplantation: Role of the Recipient’s Disease and Use of Antithrombin III Concentrates (1991) (31)
Obstetric complications and pregnancy-related venous thromboembolism: The effect of low-molecular-weight heparin on their prevention in carriers of factor V Leiden or prothrombin G20210A mutation (2012) (30)
Screening for activated protein C resistance before oral contraceptive treatment: a pilot study. (1999) (30)
Long-term effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease. (1988) (30)
Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results (2012) (30)
Evaluation of activated protein C resistance in stored plasma (1994) (29)
Low-Intensity Oral Anticoagulant Plus Low-Dose Aspirin During the First Six Months Versus Standard-Intensity Oral Anticoagulant Therapy After Mechanical Heart Valve Replacement: A Pilot Study of Low-Intensity Warfarin and Aspirin in Cardiac Prostheses (LIWACAP) (2007) (29)
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism (2018) (29)
Age and gender specific cut-off values to improve the performance of d-dimer assays to predict the risk of venous thromboembolism recurrence (2013) (29)
Clinical decision rules and D-Dimer in venous thromboembolism: current controversies and future research priorities. (2014) (28)
Old and new heparins. (2012) (28)
Antithrombin replacement in patients with sepsis and septic shock. (1999) (28)
D-dimer testing to determine the duration of anticoagulant therapy (2007) (28)
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum). (2014) (28)
Risk factors for venous thromboembolism in the elderly: results of the master registry (2008) (28)
Activated protein C resistance in deep-vein thrombosis (1994) (28)
Thalidomide–dexamethasone as up‐front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low‐dose warfarin (2010) (27)
The SAME-TT2R2 score predicts the quality of anticoagulation control in patients with acute VTE (2016) (27)
Assessment of mental ability in elderly anticoagulated patients: its reduction is associated with a less satisfactory quality of treatment (1997) (27)
Thrombophilic risk factors and peripheral arterial disease severity (2010) (27)
Venous thromboembolism, oral contraceptives and high prothrombin levels (2003) (27)
External quality assessment (EQA) for CoaguChek monitors (2010) (27)
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). (2009) (26)
Thromboprophylaxis following cesarean delivery: one site prospective pilot study to evaluate the application of a risk score model. (2012) (26)
A new rapid bedside assay for quantitative testing of D-Dimer (Cardiac D-Dimer) in the diagnostic work-up for deep vein thrombosis. (2003) (26)
Modulation of Factor V Levels in Plasma by Polymorphisms in the C2 Domain (2004) (25)
Prevalence and clinical implications of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: Insights from the START-ANTIPLATELET registry. (2021) (25)
Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. (2017) (24)
Lowered antithrombin III activity and other clotting changes in homocystinuria: effects of a pyridoxine-folate regimen. (1989) (24)
Oral Anticoagulant Therapy Control: Evidence that INR Expression Improves the Inter-Laboratory Comparability of Results - The Bologna Oral Anticoagulant Control Exercise (1987) (23)
Selection and assessment of patients treated with the novel oral anticoagulant drugs: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis (2013) (23)
Intravascular coagulation phenomena associated with prevalent fall in fibrinogen and plasminogen during L-asparaginase treatment in leukemic children. (1988) (23)
Abnormal Protac-induced coagulation inhibition chromogenic assay results are associated with an increased risk of recurrent venous thromboembolism (2010) (23)
D‐dimer use for deep venous thrombosis exclusion in elderly patients: a comparative analysis of three different approaches to establish cut‐off values for an assay with results expressed in D‐dimer units (2014) (23)
Study of a protein S gene polymorphism at DNA and mRNA level in a family with symptomatic protein S deficiency (1993) (23)
Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry (2018) (23)
A Heparin Cofactor II Mutation (HCII Rimini) Combined with Factor V Leiden or Type I Protein C Deficiency in Two Unrelated Thrombophilic Subjects (1996) (23)
Management of patients with patent foramen ovale and cryptogenic stroke (2013) (23)
PROTEASE ACTIVITIES, AS WELL AS PLASMINOGEN ACTIVATORS, CONTRIBUTE TO THE “LYTIC” STATE DURING ORTHOTOPIC LIVER TRANSPLANTATION (1993) (22)
Do Italian vascular centers look for isolated calf deep vein thrombosis? Analysis of isolated calf deep vein thromboses included in the ''Master'' Registry. (2008) (22)
Repeated graft loss caused by recurrent hepatic artery thrombosis after liver transplantation (2003) (22)
The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures (2018) (22)
A new global test for the evaluation of the protein C—protein S system (1996) (22)
Assessing recurrence risk following acute venous thromboembolism: use of algorithms (2013) (22)
II Italian intersociety consensus statement on antithrombotic prophylaxis in orthopaedics and traumatology (2012) (22)
Update on the predictive value of D-dimer in patients with idiopathic venous thromboembolism. (2010) (21)
Performance of a new, fast D-dimer test (IL Test™ D-Dimer) for the management of outpatients with suspected deep vein thrombosis in emergency situations (1999) (21)
Prevalence and predictors of dual antiplatelet therapy prolongation beyond one year in patients with acute coronary syndrome (2017) (21)
D-dimer, FVIII and thrombotic burden in the acute phase of deep vein thrombosis in relation to the risk of post-thrombotic syndrome. (2014) (20)
Systemically circulating oxidative species in human deep venous thrombosis (1998) (20)
Ascites apheresis, concentration and reinfusion for the treatment of massive or refractory ascites in cirrhosis. (1994) (20)
Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study (2019) (20)
Validation of STA-Liatest D-Di assay for exclusion of pulmonary embolism according to the latest Clinical and Laboratory Standard Institute/Food and Drug Administration guideline. Results of a multicenter management study (2016) (19)
More on: high thrombin generation and the risk of recurrent venous thromboembolism (2009) (19)
Clinical management of rivaroxaban-treated patients (2013) (19)
A guide to oral anticoagulant therapy (1998) (19)
Psychological impact of testing for thrombophilic alterations (2006) (19)
A FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers (2003) (19)
Evaluation of the prevalence of severe hyperhomocysteinemia in adult patients with thrombosis who underwent screening for thrombophilia. (2013) (19)
Changes in the Rheologic Properties of Blood after a High Altitude Expedition (1984) (19)
Residual vein thrombosis and serial D-dimer for the long-term management of patients with deep venous thrombosis. (2017) (18)
Duplex ultrasound, clinical score, thrombotic risk, and D-dimer testing for evidence based diagnosis and management of deep vein thrombosis and alternative diagnoses in the primary care setting and outpatient ward. (2014) (18)
Effect of Body Mass Index on Ischemic and Bleeding Events in Patients Presenting With Acute Coronary Syndromes (from the START-ANTIPLATELET Registry). (2019) (18)
Direct oral anticoagulants and bleeding risk (in comparison to vitamin K antagonists and heparins), and the treatment of bleeding. (2014) (18)
Evidence and clinical judgment: Treatment of cerebral vein thrombosis (2010) (18)
Study on coagulation profile of patients with cirrhosis of the liver undergoing elective fibreoptic injection sclerotherapy of oesophageal varices. (1984) (17)
Comparative evaluation of D-dimer assays for exclusion of deep venous thrombosis in symptomatic outpatients. (2003) (17)
A commentary: To screen for calf DVT or not to screen? The highly variable practice among Italian centers highlights this important and still unresolved clinical option. Results from the Italian MASTER registry (2007) (17)
Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry (2018) (17)
Activated protein C resistance: a comparison between two clotting assays and their relationship to the presence of the factor V Leiden mutation (1996) (17)
Effects of unfractioned heparin and low-molecular-weight heparin on osteoprotegerin and RANKL plasma levels in haemodialysis patients. (2011) (17)
A guide to oral anticoagulant treatment. Recommendations of the Italian federation of anticoagulation clinics (FCSA) (2003) (16)
Diagnosis of deep vein thrombosis, and prevention of deep vein thrombosis recurrence and the post-thrombotic syndrome in the primary care medicine setting anno 2014. (2015) (16)
Postoperative Versus Preoperative Initiation of Deep-Vein Thrombosis Prophylaxis with a Low-Molecular-Weight Heparin (Nadroparin) in Elective Hip Replacement (1996) (16)
Comorbidities, alone and in combination with D-dimer, as risk factors for recurrence after a first episode of unprovoked venous thromboembolism in the extended follow-up of the PROLONG study (2010) (16)
Extended prophylaxis of venous thromboembolism with fondaparinux in patients undergoing major orthopaedic surgery in Italy: a cost-effectiveness analysis (2010) (16)
Duration of anticoagulation after isolated pulmonary embolism (2016) (16)
Multicenter evaluation of a new chromogenic factor X assay in plasma of patients on oral anticoagulants. (1980) (16)
Prevalence of risk factors for venous thromboembolism in the Italian population: results of a cross-sectional study from the Master Registry (2013) (16)
Clopidogrel versus ticagrelor in high-bleeding risk patients presenting with acute coronary syndromes: insights from the multicenter START-ANTIPLATELET registry (2020) (16)
Thrombotic risk factors and cardiovascular events after endovascular intervention for peripheral arterial disease. (2011) (15)
Oral anticoagulant therapy in venous thromboembolism. (2003) (15)
Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment. (2016) (15)
G1691A factor V and G20210A FII mutations, acute ischemic stroke of unknown cause, and patent foramen ovale. (2012) (15)
Prolonged very low calorie diet in obese subjects reduces factor VII and PAI but not fibrinogen levels (1994) (15)
Evidence and Clinical Judgment: Vena cava filters (2014) (15)
Patient-level compared with study-level meta-analyses demonstrate consistency of D-dimer as predictor of venous thromboembolic recurrences. (2013) (14)
Thrombocytopenia and Mortality Risk in Patients With Atrial Fibrillation: An Analysis From the START Registry (2019) (14)
Haemorheologic and fibrinolytic evaluation in obese children and adolescents (1988) (14)
HemosIL D‐dimer HS assay in the diagnosis of deep vein thrombosis and pulmonary embolism. Results of a multicenter management study (2008) (14)
Diagnosis of deep vein thrombosis. (2006) (14)
CONTROL OF HAEMOSTASIS DURING ORTHOTOPIC LIVER TRANSPLANTATION (1988) (14)
Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, Part 1: Prevention (2009) (13)
Clinical histories and molecular characterization of two afibrinogenemic patients: insights into clinical management (2012) (13)
Biological variation of INR in stable patients on long-term anticoagulation with warfarin. (2012) (13)
Factor VIII:C Levels during Oral Anticoagulation and after Its Withdrawal (1995) (13)
ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism (2017) (13)
Improvements in the Rheologic Properties of Blood Induced by Medium-Term Treatment with Buflomedil in Diabetic Patients (1982) (13)
A guide to oral anticoagulant therapy. Italian Federation of Anticoagulation Clinics. (1998) (13)
Bleeding with anticoagulant treatments (2011) (13)
Effect of slimming on metabolic and haemorheologic patterns in a group of obese subjects. (1988) (12)
DOAC plasma levels measured by chromogenic anti‐Xa assays and HPLC‐UV in apixaban‐ and rivaroxaban‐treated patients from the START‐Register (2020) (12)
The cardiovascular risk burden of intermittent claudication (2002) (12)
Pharmacodynamic effects on blood coagulation of a new low molecular weight heparin (alfa-LMWH) in healthy volunteers and gynecological surgery patients. (1989) (12)
Fibrin D-dimer testing for venous and arterial thrombotic disease. (2005) (12)
Seasonal fibrinogen fluctuations among elderly people (1991) (12)
[Hemorrhagic complications of oral anticoagulant therapy: results of a prospective multicenter study ISCOAT (Italian Study on Complications of Oral Anticoagulant Therapy)]. (1997) (12)
Long-Term Risk for Major Bleeding During Extended Oral Anticoagulant Therapy for First Unprovoked Venous Thromboembolism (2021) (12)
Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry (2019) (12)
Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry). (2018) (11)
Very elderly patients with venous thromboembolism on oral anticoagulation with VKAs or DOACs: Results from the prospective multicenter START2-Register Study. (2019) (11)
Coagulation and fibrinolysis in orthotopic liver transplantation: role of the recipient's disease and use of antithrombin III concentrates. S. Orsola Working Group on Liver Transplantation. (1991) (11)
Managing oral anticoagulant therapy: an Italian Perspective (2003) (11)
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply (2018) (11)
Determinants of low‐quality warfarin anticoagulation in patients with mechanical prosthetic heart valves. The nationwide PLECTRUM study (2020) (11)
Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START‐Laboratory Register (2018) (11)
Treatment of Isolated Below the Knee Deep Vein Thrombosis (2016) (10)
The effect of health literacy on vaccine hesitancy among Italian anticoagulated population during COVID-19 pandemic: the moderating role of health engagement (2021) (10)
Thrombosis , 9 th Oral Anticoagulant Therapy : Antithrombotic (2012) (10)
Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study. (1991) (10)
Oral Anticoagulant Therapy: Efficacy, Safety and the Low-Dose Controversy (1999) (10)
Investigations on intravascular coagulation in liver disease: souble fibrin monomer complexes in liver cirrhosis. (1979) (10)
Stroke/thromboembolism and intracranial hemorrhage in a real-world atrial fibrillation population: the Complications of Atrial Fibrillation in the Bologna Area (CAFBO) study. (2014) (10)
D-dimer, oral anticoagulation, and venous thromboembolism recurrence. (2005) (9)
Antithrombotic drugs in peripheral obliterative arterial diseases. (1994) (9)
Inherited and acquired thrombophilic alterations in patients with superficial vein thrombosis of lower limbs (2014) (9)
The negative predictive value of D‐dimer on the risk of recurrent venous thromboembolism in patients with multiple previous events: A prospective cohort study (the PROLONG PLUS study) (2012) (9)
Complement components and fibrinogen: correlations and association with previous myocardial infarction. (1995) (9)
Specific assays of hemostasis proteins: Fibrinogen (1990) (9)
The influence of factor V Leiden and G20210A prothrombin mutation on the presence of residual vein obstruction after idiopathic deep-vein thrombosis of the lower limbs (2013) (9)
Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation. (2011) (9)
Subsegmental pulmonary embolism: is the emperor still naked? (2013) (9)
Extended treatment for venous thromboembolism: how long is long enough? (2004) (9)
D-dimer levels during and after anticoagulation withdrawal in patients with venous thromboembolism treated with non-vitamin K anticoagulants (2019) (9)
New Quantitative Enzyme Immunoassays for Degradation Products of Fibrin and Fibrinogen in Plasma: A Comparison with Other Laboratory Methods (1990) (8)
Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous thromboembolism: A systematic review and meta‐analysis (2021) (8)
Bleeding and thrombotic complications during treatment with direct oral anticoagulants or vitamin K antagonists in venous thromboembolic patients included in the prospective, observational START2-register (2020) (8)
Low in-hospital mortality rate in patients with COVID-19 receiving thromboprophylaxis: data from the multicentre observational START-COVID Register (2022) (8)
"Early thrombus removal" in iliac-femoral deep vein thrombosis for prevention of post-thrombotic syndrome. (2019) (8)
Comparative Efficacy and Safety of Sulodexide and Other Extended Anticoagulation Treatments for Prevention of Recurrent Venous Thromboembolism: A Bayesian Network Meta-analysis (2020) (8)
Foetal cerebral hemispheric atrophy and porencephaly after intrauterine exposure to maternal warfarin for mechanical prosthetic heart valve (2008) (8)
Multicentre comparison of nine coagulometers and manual tilt-tube methods for prothrombin time performance. (1983) (8)
The challenges and limitations of widespread direct oral anticoagulant treatment: practical suggestions for their best use (2016) (8)
Ischemic and bleeding risk by type 2 diabetes clusters in patients with acute coronary syndrome (2021) (8)
The incidence of heparin-induced thrombocytopenia in patients treated with low molecular weight heparin for superficial vein thrombosis. (2016) (8)
Oral contraceptive use in women with poor anticoagulant response to activated protein C but not carrying the factor V Leiden mutation increases the risk of venous thrombosis (2004) (7)
Long-term risk of recurrence after discontinuing anticoagulants for a first unprovoked venous thromboembolism: protocol for a systematic review and meta-analysis (2017) (7)
Prevalence of High Levels of Antiphospholipid Antibodies in Otherwise Unexplained Juvenile Venous Thromboembolism (1991) (7)
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study (2019) (7)
Assessment of activated partial thromboplastin time and factor IX in subjects attending an anticoagulation clinic (2000) (7)
Comparison of Anticoagulation Quality between Acenocoumarol and Warfarin in Patients with Mechanical Prosthetic Heart Valves: Insights from the Nationwide PLECTRUM Study (2021) (7)
Peripheral arterial disease has a strong impact on cardiovascular outcome in patients with acute coronary syndromes: From the START antiplatelet registry. (2020) (7)
D-dimer testing, with gender-specific cutoff levels, is of value to assess the individual risk of venous thromboembolic recurrence in non-elderly patients of both genders: a post hoc analysis of the DULCIS study (2019) (7)
D-dimer testing and recurrent venous thromboembolism after unprovoked pulmonary embolism: A post-hoc analysis of the prolong extension study (2007) (7)
Do isolated calf deep vein thrombosis need anticoagulant treatment? (2016) (7)
Screening computer‐assisted dosage programs for anticoagulation with warfarin and other vitamin K antagonists: minimum safety requirements for individual programs (2009) (7)
Perioperative Prophylaxis with a Low Molecular Weight Heparin Reduces Late PAI-1 Levels after Gynaecological Surgery (1990) (7)
Risk of Venous Thromboembolism and Clinical Manifestations in Carriers of Antithrombin , Protein C , Protein S Deficiency , or Activated Protein C Resistance (1999) (7)
Special indications for vitamin K antagonists: a review (2012) (7)
Prevention of VTE in multiple myeloma patients. (2007) (7)
Study of a G/A variation in the 3' untranslated region of prothrombin mRNA in Italian patients with venous thrombosis (1997) (6)
Transfusion Requirements Are Correlated with the Degree of Proteolysis of von Willebrand Factor during Orthotopic Liver Transplantation (1997) (6)
Elastic compression stockings for prevention of the post-thrombotic syndrome in patients with and without residual vein thrombosis and/or popliteal valve reflux. (2021) (6)
G20210A prothrombin mutation and critical limb ischaemia in patients with peripheral arterial disease. (2009) (6)
Anticoagulation resumption after intracranial hemorrhage in patients treated with VKA and DOACs. (2020) (6)
[Deep venous thrombosis. Evaluation of a non-invasive diagnostic procedure based on compression ultrasonography and measurement of D-dimer plasma levels]. (1997) (6)
Pro-thrombotic states and their diagnosis. (1994) (6)
Platelet and blood clotting activation after endoscopic sclerotherapy of oesophageal varices in liver cirrhosis. (1986) (6)
Treatment Decision-Making of Secondary Prevention After Venous Thromboembolism: Data From the Real-Life START2-POST-VTE Register (2020) (6)
Pulmonary vascular reactivity and hemorheology in patients with chronic cor pulmonale: Responses to pentoxifylline at rest and during exercise (1986) (6)
Risk of early recurrent fetal loss and levels of thrombin-activatable fibrinolysis inhibitor. (2012) (5)
Predicting Disease Recurrence in Patients with Previous Unprovoked Venous Thromboembolism: The DASH Prediction Score (2011) (5)
The new role of D-dimer as a predictor of recurrent venous thromboembolism D-Dimere: Ihre neue Rolle als Prädiktoren für rezidivierende venöse Thromboembolien (2005) (5)
Protein S activity in patients with heredofamilial protein S deficiency and in patients with juvenile venous thrombosis. Results of a functional method. (1991) (5)
Venous Thromboembolism Recurrence after a First Episode of Provoked Venous Thrombosis Due to a Transient Risk Factor. A Systematic Review of the Literature (2008) (5)
760 Prevalence of eligibility criteria for prolonged dual antithrombotic therapy in patients with PEGASUS and COMPASS phenotypes: insights from the start-antiplatelet registry (2021) (5)
d‐Dimer testing for predictive recurrence risk in venous thromboembolism: looking for a useful threshold: reply to a rebuttal (2004) (5)
An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays (2019) (5)
Warfarin anticoagulation in children made easier. (2006) (5)
Is there a role for oral anticoagulant therapy in patients with peripheral arterial disease? (2004) (5)
The risk of bleeding with anticoagulant treatments (2011) (5)
Antithrombin III replacement in orthotopic liver transplantation. (1993) (5)
No early signs of atherosclerotic alterations in carriers of inherited thrombophilia. (2010) (5)
Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study. (2020) (5)
Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study (2018) (4)
Fibrinogen/fibrin degradation products: Pathophysiology and clinical application (1993) (4)
Comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic diseases in patients with and without malignancy (2000) (4)
Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited. (2002) (4)
The prevention of venous thromboembolism recurrence in the elderly: a still open issue (2018) (4)
Endothelial activation in patients with superficial vein thrombosis (SVT) of the lower limbs. (2017) (4)
CLINICAL PREDICTION OF vTE RECURRENCE IN PATIENTS WITH PREvIOUS UNPROvOKED vENOUS THROMBOEMBOLISM. RESULTS FROM AN INDIvIDUAL-LEvEL META-ANALYSIS (2015) (4)
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster (2003) (4)
Optimal Medical Therapy on Top of Dual-Antiplatelet Therapy: 1-Year Clinical Outcome in Patients With Acute Coronary Syndrome: The START Antiplatelet Registry (2019) (4)
The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism: reply (2019) (4)
d-Dimer Testing in Patients With a First Unprovoked Venous Thromboembolism (2015) (4)
Cost‐minimization analysis of venous thromboembolism diagnosis: Comparison of standalone imaging with a strategy incorporating D‐dimer for exclusion of venous thromboembolism (2017) (4)
The effect of management models on thromboembolic and bleeding rates in anticoagulated patients: an ecological study (2019) (4)
Endocrine Aspects of Pediatric Obesity (1992) (3)
[Current criteria to determine the duration of anticoagulant therapy]. (2007) (3)
The D-dimer (DD) test to establish the duration of anticoagulation after a first unprovoked episod of venous thromboembolism (VTE); the prospective randomized “Prolong” Study on behalf of the Italian Federation of Anticoagulation Clinics (FCSA) (2005) (3)
Meta-Analysis of Long-Term Risk of Recurrent Venous Thromboembolism after Stopping Anticoagulation in Men and Women with First Unprovoked Venous Thromboembolism (2018) (3)
An evaluation of several laboratory tests and test combinations in the detection of lupus anticoagulant (1992) (3)
Design and rationale of a randomized, placebo-controlled trial on the efficacy and safety of sulodexide for extended treatment in elderly patients after a first venous thromboembolism (2020) (3)
Diagnosis and treatment of DVT and prevention of DVT recurrence and the PTS: bridging the gap between DVT and PTS in the primary care setting or outpatient ward (2017) (3)
Unprovoked or provoked venous thromboembolism: not the prevalent criterion to decide on anticoagulation extension in clinical practice of various countries—the prospective, international, observational WHITE study (2021) (3)
t-PA AND PAI-1 ANTIGENS AFTER 10 MIN. VENOUS OCCLUSION IN HEALTHY VOLUNTEERS (1988) (3)
The "lytic state" during orthotopic liver transplantation: plasminogen activators and other protease activities. (1993) (2)
Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects (2007) (2)
Clinical significance of a negative D‐dimer level in patients with confirmed venous thromboembolism. Findings from the RIETE Registry (2011) (2)
Management and Outcomes of Isolated Distal Deep Vein Thromboses: A Questionable Trend toward Long-Lasting Anticoagulation Treatment. Results from the START-Register (2021) (2)
t-PA activity elicited by venous occlusion or DDAVP infusion does not produce plasmin activity in normal subjects. (1990) (2)
[Multidisciplinary position paper on the management of patent foramen ovale in the presence of cryptogenic cerebral ischemia - Italian version 2013]. (2013) (2)
How D-dimer assay can be useful in deciding the duration of anticoagulation after venous thromboembolism: a review (2015) (2)
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study (2022) (2)
287 Euglobulin lysis time (ELT) after 10 min. venous occlusion (VO) did not discriminate normal subjects from vascular patients, nor identify patients with altered plasminogen or PA-I levels (1988) (2)
Bridging therapy in oral anticoagulated patients: focusing on how to do it (2007) (2)
Prophylaxis of venous thrombosis after gynaecological surgery: a controlled pilot study of defibrotide. (1992) (2)
D‐dimer testing and venous thromboembolism: four view points (2005) (2)
The direct oral anticoagulants may also be effective against the risk of post-thrombotic syndrome (2019) (2)
A New Fibrinogen Variant With Abnormal Gamma Chain : Fibrinogen Haifa (1981) (2)
Oral anticoagulant therapy today: efficacy, safety, open problems. (2000) (2)
Emerging drugs for venous thromboembolism (2010) (2)
[High negative predictive value for recurrence of venous thromboembolism with d-dimer carried out three months after the suspension of treatment with oral anticoagulants in patients over 60]. (1998) (2)
Do women with venous thromboembolism bleed more than men during anticoagulation? Data from the real-life, prospective START-Register (2021) (2)
Fibrinogen In Liver Cirrhosis. Sialic Acid Content Of Fibrinogen In Moderate And Severe Cirrhosis And Relation To Thrombin Time (1981) (2)
The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study: reply (2014) (2)
[Anticoagulant therapy in patients with atrial fibrillation: the experience of the Centers of Surveillance. Study group of the "Italian Study on Complications of Oral Anticoagulant Therapy" (ISCOAT)]. (1996) (2)
Italian intersociety consensus statement on antithrombotic prophylaxis in hip and knee replacement and in femoral neck fracture surgery. (2011) (2)
Anticoagulation therapy: bleeding and thromboembolic complications (1996) (1)
Association of Antiplatelet and Anticoagulant Treatment in Patients with Mechanical Prosthetic Heart Valves. Data from the Observational Multicentre PLECTRUM Study (2021) (1)
Baseline Thrombophilic Alterations and Risk of Venous Thromboembolism in 266 Multiple Myeloma Patients Primarily Treated with Thalidomide and High-Dose Dexamethasone. (2007) (1)
Fibrinogen In Liver Cirrhosis. Lack Of Correlation Between Soluble Fibrin Monomer Complexes And Fibrinopeptide A Levels (1981) (1)
Residual venous obstruction and D-dimer as risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis in the prolong study (2008) (1)
Fibrinogen as a risk index and a pathogenic factor for thrombosis (1990) (1)
Long-term risk of major bleeding after discontinuing anticoagulation for unprovoked venous thromboembolism: a systematic review and meta-analysis (2021) (1)
Prescribing anticoagulation medication for the elderly (2012) (1)
Prevalence of pulmonary embolism among patients with recent onset of dyspnea on exertion. A cross-sectional study. (2023) (1)
Blood Viscosity and Platelet Aggregation in Male and Female Patients with Transient Ischaemic Attacks (TIA) (1979) (1)
Transient coagulation abnormalities following endoscopic sclerosis of esophageal varices. (1983) (1)
[Significance of the rheological properties of blood in peripheral vascular pathology]. (1985) (1)
Effect of body mass index on ischemic and bleeding events in patients presenting with acute coronary syndromes: insights from the START-ANTIPLATELET registry (2020) (1)
Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial (2022) (1)
Recurrence after stopping anticoagulants in women with combined oral contraceptive‐associated venous thromboembolism: A systematic review and meta‐analysis (2022) (1)
Pregnancy and venous thrombosis (2009) (1)
Ticagrelor versus Clopidogrel in high bleeding risk patients presenting with Acute Coronary Syndromes: insights from the multicenter START-ANTIPLATELET registry (2020) (1)
Hyperfibrinolysis, t-PA and u-PA levels during orthotopic liver transplantation (OLT) (1990) (1)
Sex‐based difference in anticoagulated patients with mechanical prosthetic heart valves and long‐term mortality risk (2021) (1)
[Action of pentoxifylline on the velocity of aortic blood in valvular stenosis of the aorta]. (1983) (1)
LONG TERM EFFECTS OF TICLOPIDINE ON FIBRINOGEN AND HAEMORHEOLOGY IN PATIENTS WITH PERIPHERAL ARTERIAL DISEASES (1987) (1)
Warfarin prescription in patients with nonvalvular atrial fibrillation and one non–gender‐related risk factor (CHA2DS2VASc 1 or 2): A treatment dilemma (2018) (1)
PO-90 Clinical characteristics of cancer associated acute venous thromboembolism: findings from the MASTER Registry (2007) (1)
Haemorheologic effects of plasmin and thrombininduced fibrinogen derivatives: An in vitro study (1986) (1)
Comparison of five methods for fibrinogen measurement in various clinical conditions (1992) (1)
Anticoagulation for venous thromboembolism (2012) (1)
[Home use of an ambulatory monitor for the determination of prothrombin time (coaguchek) in patients treated with oral anticoagulants. Multicenter prospective study]. (1999) (1)
Influence of clinical presentation, site, and extent of venous thrombosis on decision about duration of anticoagulation: Data from the international, prospective, observational WHITE study. (2022) (1)
EUGLOBULIN LYSIS TIME AFTER 10 MIN. VENOUS OCCLUSION DOES NOT IDENTIFY PATIENTS WITH ALTERED SPECIFIC FIBRINOLYTIC TESTS (1988) (1)
Association of membranous nephropathy with familial resistance to activated protein C. (1995) (1)
EFFECTS OF GABEXATE MESILATE (FOY), A NEW SYNTHETIC SERINE PROTEASE INHIBITOR, ON BLOOD COAGULATION IN PATIENTS WITH DIC (1987) (1)
394 Hyperfibrinolysis and during DIC orthotopic liver transplantation (OLT). An indication for intraoperative at III concentrates (1988) (1)
[The BAFTA study]. (2008) (1)
Thrombophilia testing in the real-world clinical setting of thrombosis centres taking part in the Italian Start 2-Register. (2021) (1)
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply (2013) (1)
286 t-PA antigen and other fibrinolytic parameters after 10 min. venous occlusion in young healthy subjects (1988) (1)
Thromboembolic Complications in COVID-19 Patients Hospitalized in Italian Ordinary Wards: Data from the Multicenter Observational START-COVID Register (2022) (1)
C0310 Risk stratification models to predict bleeding events in very old patients on VKA treatment for venous thromboembolism. Results of a prospective multicenter study (2012) (1)
, Centres for Anticoagulation of a Prospective Collaborative Study on Elderly Patients Followed by Italian Bleeding Risk in Very Old Patients on Vitamin K Antagonist Treatment : Results (2011) (1)
Hemorheologic changes in patients with a history of stroke or cerebral remittent ischemic attacks (1985) (1)
Risk of Recurrence after Stopping Anticoagulants in Women with Combined Oral Contraceptive-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis (2021) (1)
Venous thromboembolism in renal transplant recipients: Results of Venous thromboEmbolism in renal Transplant Recipients- Italian Study - VETRIS. (2020) (0)
Coagulation And Hem0Rhe0L0Gy In Cerebrovascular Disease. Differences Reated To Angiographic Findings And Sex (1981) (0)
Anticoagulation: Heparins and Vitamin K Antagonists (2016) (0)
Quality of warfarin anticoagulation in adults with short bowel syndrome on home parenteral nutrition. (2022) (0)
LETTERS to the EDITORTiclopidine (1991) (0)
TEMPORARY REMOVAL: PO-58: Cancer-associated venous thromboembolism: the Onco-VTE START2 - Registry. (2022) (0)
Bleeding and mortality risk in patients implanted with mechanical prosthetic heart valves with and without thrombocytopenia. Insights from the nationwide PLECTRUM registry (2022) (0)
Fibrinogen-Fibrin Monomer Complexes in Cirrhosis of The Liver (1977) (0)
VENOUS THROMBOEMBOLISM SECONDARY TO HOSPITALIZATION FOR COVID-19 DISEASE: PATIENT MANAGEMENT AND LONG-TERM OUTCOMES (2023) (0)
Ticlopidine (1991) (0)
A new warfarin dosing algorithm including VKORC1 3730 G > A polymorphism: comparison with results obtained by other published algorithms (2012) (0)
Haemorheology in treated polycythaemia vera: The role of hypochromic mycrocytosis and of plasma viscosity (2016) (0)
Modifications of the hemorrheological parameters with reference to the use of autologous or homologous blood in 25 cases of aorto-coronary by-pass. (1986) (0)
Haemorheological results in a large multicentre study of claudicants treated with ketanserin (2016) (0)
COST-EFFECTIVENESS OF COMPUTER-ASSISTED ANTICOAGULANT DOSAGE CLINICAL STUDY (2007) (0)
ANTICOAGULATION THERAPY : BLEEDING AND THROMBOEMBOLIC COMPLICATIONS. AUTHOR'S REPLY (1996) (0)
Normalization of Plasma Antithrombin Activity in Patients Requiring Hemodynamic and/or Respiratory Support has Anti-inflammatory Properties Related to Survival (1999) (0)
FIBRINOGEN IN LIVER CIRRHOSIS. FIBRIN MONOMER COMPLEXES AND DYSFIBRINOGENAEMIA WITH HIGH SIALIC ACID CONTENT (1982) (0)
Anticoagulation Duration After First Venous Thromboembolism: Real-Life Data From the International, Observational WHITE Study (2021) (0)
[Prevention of severe venous thrombosis in pulmonary embolism]. (1998) (0)
Recurrences and bleeding during extended treatment of patients with venous thromboembolism: results of the international, prospective, observational WHITE study. (2023) (0)
NATURAL MUTATIONS IN THE EGF4 DOMAIN OF PROTEIN S PRODUCE EXTENDED CONFORMATIONAL CHANGES AND ALTER PHOSPHOLIPID AND C4BBP INTERACTIONS (2006) (0)
OC-15 - Risk factors for cancer development after idiopathic venous thromboembolism. (2016) (0)
Changes in fibrinogen, factor VII and PAI-1 in obese women submitted to a very low calorie diet (VLCD) (1992) (0)
Rivaroxaban for the Treatment of Symptomatic Isolated Distal Deep Vein Thrombosis – RIDTS Study (2021) (0)
A multicentre randomised clinical end-point study of PARMA 5 computer-assisted oral anticoagulant dosage: On behalf of the European Action on Anticoagulation (2008) (0)
Evaluation of Coaguchek®Pro II coagulation testing device performance to assess direct oral anticoagulant action. The DOAC-CHECK study (2022) (0)
[Prevention and treatment of deep venous thrombosis: prevention of pulmonary embolism]. (1994) (0)
Optimal long-term pharmacological treatment of patients with venous thromboembolism that was unprovoked or associated with weak risk factors (2017) (0)
Predicting the risk of thromboembolic recurrences: the value of D-dimer (2003) (0)
[Therapeutic ranges of oral anticoagulant therapy in different diseases. Guidelines of the Federation of Centers of Surveillance of Patients on Anticoagulation. Ad hoc Study Group]. (1996) (0)
COVID-19 pandemic affects the ability of negative D-dimer to identify venous thromboembolism patients at low risk of recurrence: insights from the Apidulcis study (2022) (0)
0.10b Low-molecular-weight heparin for prevention of obstetric complications in carriers of factor V Leiden or PT-G20210A mutation (2011) (0)
Author / Subject Indexes (2004) (0)
The influence of VKORC1 3730 G > A polymorphism on warfarin dose: reply (2012) (0)
Safety and efficacy of treatment with vitamin K antagonists in patients managed in a network of anticoagulation services or as routine general care (2022) (0)
BRIEF COMMUNICATION PLATELFT AND BLOOD QMITING ACTIVATION AFTER ENJXSCOPIC SCLEROTHERAPY OF OESOPHAGEAL VARICFS IN LIVER CIRRHOSIS (1986) (0)
Intracranial hemorrhage recurrence on vitamin K antagonist: severity of the first episode and HASBLED score fail to identify high-risk patients from the CHIRONE study (2017) (0)
Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results (2022) (0)
ATIH TREATMENT IN PATIENTS (PTS) REQUIRING HEMODINAMYC (H) AND RESPIRATORY (R) SUPPORT (S): 650 (1997) (0)
PCV11 Comparative Efficacy and Safety of Sulodexide for Prevention of Recurrent Venous Thromboembolism: A Network Meta-Analysis (2020) (0)
Significance of rheologic properties of the blood in pathology of the peripheral vascular system (1984) (0)
Low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. (2003) (0)
[Effect of pentoxifylline on pulmonary hemodynamics]. (1988) (0)
Markers of hypercoagulability in patients undergoing cardiopulmonary by-pass (CPB) operation: The effect of intra-operative aprotinin administration (1994) (0)
The American College of Chest Physicians score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism—Response (2019) (0)
[The surveillance of the anticoagulated patient: a multidisciplinary problem]. (1990) (0)
Optimal duration of anticoagulant therapy in patients with venous thromboembolism (2018) (0)
Clinical phenotypes of atrial fibrillation and risk of mortality: a cluster analysis (2020) (0)
[Levels of total plasma homocysteine after methionine intake in a group of healthy subjects in Northern + Italy. Relationship with age, gender, and nutritional status]. (1999) (0)
British Medical Journal (1861) (0)
PO-33 D-dimer testing to determine duration of anticoagulation and risk of occult cancer after a first episode of idiopathic venous thromboembolism: the extended follow-up of the PROLONG study (2010) (0)
[ANMCO Position paper: Recommendations for the follow-up of patients with pulmonary thromboembolism]. (2016) (0)
Vascular endothelial dysfunction in primary open angle glaucoma (2009) (0)
[From heparin to synthetic antithrombotic drugs]. (2001) (0)
Genetic variants of CYP2C9 cytochrome do not account for high intraindividual variability of patients in their response to oral anti-coagulants (OA): a collaborative controlled study (2003) (0)
Biological Determinants of Fasting and Postload Plasma Homocysteine Levels in Healthy Italian Subjects. (2002) (0)
[Hemorheologic and coagulation study in a group of patients with diabetic retinopathy]. (1984) (0)
[Early diagnosis of deep vein thrombosis: clinical, instrumental and laboratory approach]. (1998) (0)
[The fibrinolytic system. Relations between hemorrheology and microcirculation]. (1981) (0)
Title Page / Table of Contents, Vol. 19, Supplement 1, 1989 (1989) (0)
A Comparison Of Various Methods For Measuring At III In Different Clinical Conditions (1981) (0)
[Recurrences and new vein thrombotic events during oral anticoagulant therapy in patients treated for previous vein thromboembolism. Data from the literature and results of the ISCOAT study]. (1999) (0)
ACTIVATED PROTEIN C RESITANCE IN DEEP-VEIN THROMBOSIS (1994) (0)
Ischemic and bleeding risk stratification in diabetic patients after acute coronary syndrome based on insulin requirement (2020) (0)
Bleeding risk and hemorrhage: why it happens and what to do about it (2005) (0)
Thrombosis: 17th International Congress, Bologna, October 2002: Reports (2003) (0)
Long term clinical outcomes of cancer associated venous thromboembolism: findings from the MASTER registry (2012) (0)
Two polymorphisms (2120Met/Thr, 2194 Asp/Gly,) in the C2 domain of factor V are associated with reduced factor V levels. (2002) (0)
Correlation between Thromboplastin Sensitivity and In Vitro F1 + 2 Generation Rate (1995) (0)
Premature Vascular Disease in Homocysteinaemia: A Topic Presented at a Symposium Held during the 10th International Congress on Thrombosis, Athens, May 1988 (1989) (0)
Clinical Phenotypes of Atrial Fibrillation and Mortality Risk—A Cluster Analysis from the Nationwide Italian START Registry (2022) (0)
Risk factors for highly unstable response to oral anticoagulation: response to Murphy (2005) (0)
[Oral anticoagulants]. (1999) (0)
Major bleedings in mechanical prosthetic heart valves patients on Vitamin K antagonist treatment. Data from the PLECTRUM Study (2022) (0)
Validation and Updating of a Prognostic Survival Model The Vienna Prediction Model (2013) (0)
Catheter-related central venous thrombosis: The development of an Italian nationwide Consensus Paper (2007) (0)
PO-24 Elevated levels of Factor VIII in patients with multiple myeloma treated with thalidomide (2007) (0)
Coagulation Studies in Chronic Active Hepatitis (1976) (0)
[Preliminary study for the evaluation of the feasibility of a multicenter clinical trial for the evaluation of the therapeutic efficacy of an antithrombin III concentration (Immuno) in the intravascular coagulation syndrome]. (1990) (0)
D-DIMER AND SERUM FDP IN GYNAECOLOGICAL SURGERY AND DIC PATIENTS (1987) (0)
A new LMW Dermatan Sulfate (Desmin). Effects on coagulation and fibrinolysis (1992) (0)
Thrombotic burden, D-dimer levels and complete compression ultrasound for diagnosis of acute symptomatic deep vein thrombosis of the lower limbs. (2022) (0)
[Diagnostic accuracy of various methods for the measurement of D-dimers in patients with suspected deep venous thrombosis]. (1999) (0)
Are high D-Dimer levels in patients with acute VTE a sign of possible occult cancer? (2012) (0)
The recent clinical trials on use of the novel direct oral anticoagulants in patients with venous thromboembolism: a review (2014) (0)
Interrelations between haemorheology, thrombosis and fibrinolysis (2016) (0)
Significance of antithrombin III measurement in patients admitted to an intensive care unit (1984) (0)
PCV38 EXTENDED PROPHYLAXIS OF VENOUSTHROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY: A PHARMACOECONOMIC STUDY (2008) (0)
Relations among glycoregulation, lipids, coagulation and haemorheological values and blood pressure in obese children. (1990) (0)
Involvement of the MLL gene in T-lineage acute lymphoblastic leukemia (2002) (0)
[Proposed guidelines for the correct application of ultrasonography methods in the diagnosis of deep venous thrombosis of the legs]. (1999) (0)
THE COURSE OF D-DIMER AND FACTOR VIII LEVELS DURING THE ACUTE PHASE OF LEG DEEP VENOUS THROMBOSIS AND RELATIONSHIP WITH THE THROMBOTIC BURDEN (2007) (0)
A new membrane for dialysis reportedly not requiring heparin: effects on blood clotting and platelet function (1990) (0)
Fibrin Formation in Liver Cirrhosis: Acquired Dysfibrinogenaemia or Hampered Polymerisation? (1979) (0)
The ICMJE editors' proposal on sharing individual data collected in clinical trials: Comments. (2016) (0)
Hyperfibrinolysis but not hypercoagulability after a new ascites-apheresis procedure in liver cirrhosis patients with refractory ascites (1996) (0)
Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding. (2023) (0)
4110Thromboembolic and bleeding risk of patients with left-sided mechanical heart prostheses: the FCSA-START-Valvole Study (2017) (0)
High Altitude Expeditions: Haemorheologic effects (2016) (0)
[Venous color echo-doppler in diagnosis of proximal deep vein thrombosis: variability with different operators and comparison with phlebography]. (1998) (0)
Relationship between peripheral arterial diseases and hemorheologic disorders. Pathophysiologic and therapeutic implications (2016) (0)
Intraoperative autotransfusion does not induce deterioration in haemorheologic conditions during and after cardiopulmonary by-pass surgery (2016) (0)
Aprotinin improves early graft survival but does not reduce the activation of matrix metalloproteinases in orthotopic liver transplantation. (2001) (0)
HEALTH ECONOMIC EVALUATION OF A DIAGNOSTIC STRATEGY FOR VENOUS THROMBOEMBOLISM (2016) (0)
Laboratory assessment of lupus anticoagulant: Comparative evaluation of single tests and test combinations (1992) (0)
The Mediterranean League Against Thromboembolic Diseases / Spanish Society of Thrombosis and Haemostasis (1994) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Gualtiero Palareti?

Gualtiero Palareti is affiliated with the following schools: